News
Quidel to Present Today at 13th Annual Piper Sandler Med-Tech and Diagnostics California Bus Tour
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present
Agilent Sets the Standard in Customer Flexibility with Analytical Technology Subscription Model
Agilent Technologies Inc. (NYSE: A) today announced its first-ever instrument subscription program, designed to meet the needs of customers with dynamic businesses who want the latest technology
Illumina Welcomes Kathryne Reeves as Chief Marketing Officer
Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020. Reeves brings more than 25 years of marketing and general
Ipsen to Present Results From MOVE, the First Global Phase III Trial in Fibrodysplasia Ossificans Progressiva (FOP), at ASBMR 2020 Annual Meeting
Ipsen (Euronext: IPN; ADR: IPSEY) today announced results from the MOVE trial, the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP), to be presented during
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against
Quidel Concludes Sofia® SARS Antigen Investigation From Vermont
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
Quidel to Update Packaging of Point-of-Care Sofia® SARS Antigen Test for COVID-19 to Include Either Nasal or Nasopharyngeal Swabs
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that labeling for
Agilent Reports Third-Quarter Fiscal Year 2020 Financial Results
Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.26 billion for the third quarter ended July 31, 2020, a decline of 1% compared to the third quarter of 2019 and down 3.1% on a core(
Agilent to Expand State-of-the-Art Manufacturing Capacity for Nucleic Acid-Based Therapeutics
Agilent Technologies Inc. (NYSE: A) today announced it will expand its state-of-the-art production facility in Frederick, Colorado, that develops and manufactures “oligos,” which are short DNA and
Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Health Canada Authorization
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
Dexcom Appoints Karen Dahut to Board of Directors
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring, today announced the appointment of Karen Dahut to its Board of Directors, effective immediately.
Ms
State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that the State of Maryland
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
-
Quentin Blackford, Chief Operating Officer and Chief
Illumina to Webcast Upcoming Investor Conference Presentation
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
UBS Genomics 2.0 and
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external
Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome
Illumina, Inc. (Nasdaq:ILMN). The power to make bigger discoveries is here with the launch of NovaSeqTM 6000 v1.5 Reagent Kit. The new NovaSeq 6000 v1.5 Reagent Kits aim to make whole genome
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020.
Second quarter 2020 results reflect the impact of the global COVID-19 pandemic:
Humana Ranks #1 for Customer Satisfaction for Mail Order in J.D. Power Pharmacy Study for Third Year in a Row
Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), has been named the best in Mail Order Pharmacy customer satisfaction in the J.D. Power 2020 U.S. Pharmacy Study. It’s the third consecutive
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT
FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BLENREP (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed
LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival in First-Line ALK-Positive Lung Cancer
Pfizer Inc. (NYSE:PFE) today announced that the Phase 3 CROWN study of LORBRENA® (lorlatinib) in people with previously untreated advanced anaplastic lymphoma kinase (ALK)-positive non-small cell
Bayer: Diese Gewinnwarnung ist gar nicht das Problem!
Der Leverkusener Chemie- und Pharmagigant Bayer (WKN: BAY001) legte heute früh seine aktuellen Quartalszahlen vor. Demnach wurde in Q2 ein Umsatz in Höhe von 10,05 Milliarden Euro bei einem EBIT von
Quidel Receives Preliminary Contract Leading to Definitive Agreement for $71 Million Under NIH’s RADx-ATP Program to Accelerate the Expansion of Its Manufacturing Capacity for Sofia® SARS-CoV-2 Antigen Detection Test for Rapid Diagnosis of COVID-19
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has
Pfizer and BioNTech to Supply Japan with 120 Million Doses of their BNT162 mRNA-based Vaccine Candidate
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based